Health
CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A – News-Medical.Net
Researchers at Children’s Hospital of Philadelphia have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia…
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies,…
-
General17 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
Business23 hours ago3 of the best ASX ETFs for beginners to buy with $1,000
-
Noosa News22 hours agoToyah Cordingley’s accused killer ‘3.7 billion times more likely than not’ to have contributed to DNA sample near burial site, court told
-
Business21 hours agoWhy this ASX 200 tech stock could rise 20%